F-star Therapeutics Presents Clinical Data on FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, at ESMO-IO 2022 Congress Dec 6, 2022 06:00AM
F-star Therapeutics Presents Clinical Data on FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, at ESMO-IO 2022 Congress Dec 6, 2022 06:00AM
F-Star Therapeutics (FSTX) Reports Publication of Phase 1 Dose-Escalation Trial of FS118 Nov 7, 2022 07:31AM
F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research Nov 7, 2022 07:30AM
F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research Nov 7, 2022 07:30AM
View Older Stories

Aug 11, 2022 08:00AM F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
Aug 11, 2022 08:00AM F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
Jul 20, 2022 08:05AM F-Star Therapeutics (FSTX) Enters License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody
Jul 20, 2022 08:00AM F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody
Jul 20, 2022 08:00AM F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody
May 10, 2022 08:00AM F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 10, 2022 08:00AM F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 2, 2022 09:00AM F-star Therapeutics to Announce First Quarter Results and Host Conference Call on Tuesday, May 10th, 2022
May 2, 2022 09:00AM F-star Therapeutics to Announce First Quarter Results and Host Conference Call on Tuesday, May 10th, 2022
Apr 8, 2022 08:00AM F-star Therapeutics Presents a Novel LAG-3 Reduction and Shedding Mechanism with FS118 at AACR 2022
Apr 8, 2022 08:00AM F-star Therapeutics Presents a Novel LAG-3 Reduction and Shedding Mechanism with FS118 at AACR 2022
Mar 14, 2022 08:00AM F-star Therapeutics Reports Full-Year 2021 Financial Results and Provides Corporate Update
Mar 10, 2022 08:00AM F-star Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
Mar 10, 2022 08:00AM F-star Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
Mar 2, 2022 08:00AM F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022
Mar 2, 2022 08:00AM F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022
Mar 1, 2022 08:00AM F-star Therapeutics Appoints James Sandy as Chief Development Officer
Mar 1, 2022 08:00AM F-star Therapeutics Appoints James Sandy as Chief Development Officer
Jan 20, 2022 08:05AM F-Star Therapeutics Inc. (FSTX) Issues US Patent for FS118
Jan 20, 2022 08:05AM F-Star Therapeutics Inc. (FSTX) Announces Issuance of U.S. Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 and LAG-3
Jan 20, 2022 08:00AM F-star Announces Issuance of U.S. Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 and LAG-3
Jan 20, 2022 08:00AM F-star Announces Issuance of U.S. Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 and LAG-3
Jan 7, 2022 08:00AM F-star Therapeutics to Participate in Upcoming Investor Conferences
Jan 7, 2022 08:00AM F-star Therapeutics to Participate in Upcoming Investor Conferences
Jan 5, 2022 08:09AM F-Star Therapeutics (FSTX) Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
Jan 5, 2022 08:00AM F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
Jan 5, 2022 08:00AM F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
Dec 7, 2021 09:05AM F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021
Dec 7, 2021 09:05AM F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021
Nov 29, 2021 08:00AM F-star Therapeutics to Host Virtual R&D Day on December 6, 2021
Nov 29, 2021 08:00AM F-star Therapeutics to Host Virtual R&D Day on December 6, 2021
Nov 12, 2021 08:00AM F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference
Nov 12, 2021 08:00AM F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference
Nov 10, 2021 08:00AM F-star Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Nov 10, 2021 08:00AM F-star Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Nov 1, 2021 08:00AM F-star Therapeutics to Announce Third Quarter Results and Host Conference Call on November 10, 2021
Nov 1, 2021 08:00AM F-star Therapeutics to Announce Third Quarter Results and Host Conference Call on November 10, 2021
Oct 20, 2021 08:01AM F-Star Therapeutics (FSTX) Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics
Oct 20, 2021 08:00AM F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics
Oct 20, 2021 08:00AM F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics
Sep 16, 2021 08:06AM F-Star Therapeutics Inc. (FSTX) to Present FS120 Phase 1 Trial-in-Progress Update at ESMO
Sep 16, 2021 08:00AM F-star Therapeutics to Present FS120 Phase 1 Trial-in-Progress Update at ESMO 2021
Sep 16, 2021 08:00AM F-star Therapeutics to Present FS120 Phase 1 Trial-in-Progress Update at ESMO 2021
Sep 9, 2021 09:00AM F-star Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Sep 9, 2021 09:00AM F-star Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Aug 12, 2021 08:00AM F-star Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Aug 12, 2021 08:00AM F-star Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Aug 10, 2021 08:10AM F-Star Therapeutics Inc. (FSTX) Granted Composition of Matter Patent for its Novel Second Generation STING Agonist, SB 11285
Aug 10, 2021 08:00AM F-star Therapeutics is Granted Composition of Matter Patent for its Novel Second Generation STING Agonist, SB 11285
Aug 10, 2021 08:00AM F-star Therapeutics is Granted Composition of Matter Patent for its Novel Second Generation STING Agonist, SB 11285
View Older Stories